Education
About Us
Working with TipRanks
Follow Us
Candel Therapeutics, Inc. (CADL)
:CADL
CADL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.79 - $14.60
Previous CloseN/A
Volume524.53K
Average Volume (3M)984.07K
Market Cap
$324.74M
Enterprise Value$4.34M
Total Cash (Recent Filing)$92.17M
Total Debt (Recent Filing)$10.01M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Sep 03, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding53,324,074
10 Day Avg. Volume1,090,546
30 Day Avg. Volume984,073
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)-0.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.01
Enterprise Value/Revenue1.22
Enterprise Value/Gross Profit-17.41
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$22.60Price Target Upside271.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Candel Therapeutics News
PremiumCompany Announcements
Candel Therapeutics Announces $15M Stock Offering
PremiumCompany Announcements
Candel Therapeutics Appoints Charles Schoch as CFO
PremiumCompany Announcements
Candel Therapeutics Elects New Directors at Annual MeetingBulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe Phase 3 trial for CAN-2409 met the primary endpoint of disease-free survival with a 30% decrease in disease recurrence, setting the stage for a BLA filing.
Regulatory DesignationsCAN-2409 has received Regenerative Medicine Advanced Therapy and Fast Track designations from the FDA for the treatment of newly diagnosed localized prostate cancer in patients at intermediate-to-high-risk.
Bears Say
Funding RequirementsThe company will require additional funding to get to FDA approval and ultimately commercial launch.
Overall Survival BenefitNot being positioned to show an overall survival benefit given ADT remains a downstream option appears to miss the point.
Ownership Overview
18.48% Insiders
16.25% Mutual Funds
13.70% Other Institutional Investors
46.23% Public Companies and Individual Investors
CADL FAQ
What was Candel Therapeutics, Inc.’s price range in the past 12 months?
Candel Therapeutics, Inc. lowest stock price was $3.79 and its highest was $14.60 in the past 12 months.
What is Candel Therapeutics, Inc.’s market cap?
Candel Therapeutics, Inc.’s market cap is $324.74M.
When is Candel Therapeutics, Inc.’s upcoming earnings report date?
Candel Therapeutics, Inc.’s upcoming earnings report date is Sep 03, 2025 which is in 54 days.
How were Candel Therapeutics, Inc.’s earnings last quarter?
Candel Therapeutics, Inc. released its earnings results on May 13, 2025. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of -$0.375 by $0.505.
Is Candel Therapeutics, Inc. overvalued?
According to Wall Street analysts Candel Therapeutics, Inc.’s price is currently Undervalued.
Does Candel Therapeutics, Inc. pay dividends?
Candel Therapeutics, Inc. does not currently pay dividends.
What is Candel Therapeutics, Inc.’s EPS estimate?
Candel Therapeutics, Inc.’s EPS estimate is -0.16.
How many shares outstanding does Candel Therapeutics, Inc. have?
Candel Therapeutics, Inc. has 53,324,074 shares outstanding.
What happened to Candel Therapeutics, Inc.’s price movement after its last earnings report?
Candel Therapeutics, Inc. reported an EPS of $0.13 in its last earnings report, beating expectations of -$0.375. Following the earnings report the stock price went up 7.784%.
Which hedge fund is a major shareholder of Candel Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CADL
Candel Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.60 (271.10% Upside)
$22.60 (271.10% Upside)
Blogger Sentiment
Bullish
CADL Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 526.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 11.8%
Last 30 Days ▼ 11.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.67%
12-Months-Change
Fundamentals
Return on Equity
-98.14%
Trailing 12-Months
Asset Growth
207.22%
Trailing 12-Months
Company Description
Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
CADL Stock 12 Month Forecast
Average Price Target
$22.60
▲(271.10%Upside)
Technical Analysis
aTyr Pharma
―
Clinigence Holdings
―
Inventiva
―
Compass Therapeutics
―
Olema Pharmaceuticals
―